Cytosorbents Future Growth

Future criteria checks 2/6

Cytosorbents is forecast to grow earnings and revenue by 53.8% and 22.3% per annum respectively while EPS is expected to grow by 55.4% per annum.

Key information

53.8%

Earnings growth rate

55.4%

EPS growth rate

Medical Equipment earnings growth	17.1%
Revenue growth rate	22.3%
Future return on equity	n/a
Analyst coverage	Low
Last updated	14 Nov 2024

Recent future growth updates

Recent updates

The Market Lifts Cytosorbents Corporation (NASDAQ:CTSO) Shares 43% But It Can Do More

Oct 01

Investors Continue Waiting On Sidelines For Cytosorbents Corporation (NASDAQ:CTSO)

Jul 04

Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

Mar 16

Take Care Before Jumping Onto Cytosorbents Corporation (NASDAQ:CTSO) Even Though It's 28% Cheaper

Jan 06

Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt?

Nov 10

Shareholders Should Be Pleased With Cytosorbents Corporation's (NASDAQ:CTSO) Price

Jul 13

CytoSorbents stock rises on US DoD contract to develop device for universal plasma

Sep 09

We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

Sep 02

CytoSorbents gets reimbursement for CytoSorb in Turkey

Aug 23

CytoSorbents stock rises 10% as Israel approves coverage for CytoSorb system

Aug 17

Cytosorbents GAAP EPS of -$0.25 misses by $0.13, revenue of $8.5M misses by $1.06M

Aug 02

Earnings and Revenue Growth Forecasts

NasdaqCM:CTSO - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	53	-6	-12	-11	3
12/31/2025	43	-13	-21	-20	3
12/31/2024	39	-17	-26	-26	3
9/30/2024	38	-19	-19	-18	N/A
6/30/2024	37	-26	-22	-21	N/A
3/31/2024	37	-28	-24	-23	N/A
12/31/2023	36	-29	-23	-22	N/A
9/30/2023	37	-23	-22	-21	N/A
6/30/2023	36	-26	-24	-22	N/A
3/31/2023	35	-31	-30	-23	N/A
12/31/2022	35	-33	-35	-28	N/A
9/30/2022	36	-41	-36	-28	N/A
6/30/2022	38	-36	-34	-26	N/A
3/31/2022	41	-29	-24	-20	N/A
12/31/2021	43	-25	-18	-14	N/A
9/30/2021	44	-16	-12	-10	N/A
6/30/2021	45	-10	-11	-9	N/A
3/31/2021	43	-9	-7	-5	N/A
12/31/2020	41	-8	-7	-6	N/A
9/30/2020	36	-11	-10	-9	N/A
6/30/2020	32	-17	-12	-11	N/A
3/31/2020	28	-18	-17	-16	N/A
12/31/2019	25	-19	-18	-17	N/A
9/30/2019	24	-21	-17	-15	N/A
6/30/2019	23	-17	-14	-13	N/A
3/31/2019	23	-19	-14	-13	N/A
12/31/2018	23	-17	-12	-11	N/A
9/30/2018	21	-15	-10	-9	N/A
6/30/2018	19	-14	N/A	-8	N/A
3/31/2018	17	-10	N/A	-7	N/A
12/31/2017	15	-9	N/A	-6	N/A
9/30/2017	14	-11	N/A	-7	N/A
6/30/2017	12	-10	N/A	-7	N/A
3/31/2017	11	-11	N/A	-7	N/A
12/31/2016	10	-12	N/A	-7	N/A
9/30/2016	8	-9	N/A	-8	N/A
6/30/2016	7	-10	N/A	-8	N/A
3/31/2016	6	-5	N/A	-8	N/A
12/31/2015	5	-9	N/A	-9	N/A
9/30/2015	4	-17	N/A	-9	N/A
6/30/2015	4	-17	N/A	-9	N/A
3/31/2015	4	-21	N/A	-8	N/A
12/31/2014	4	-19	N/A	-6	N/A
9/30/2014	4	-9	N/A	-5	N/A
6/30/2014	4	-8	N/A	-4	N/A
3/31/2014	3	-7	N/A	-3	N/A
12/31/2013	2	-7	N/A	-3	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CTSO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CTSO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CTSO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CTSO's revenue (22.3% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: CTSO's revenue (22.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CTSO's Return on Equity is forecast to be high in 3 years time

Cytosorbents Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Forecast to breakeven in 2026

Consensus EPS estimates upgraded to US$0.31 loss

No longer forecast to breakeven

No longer forecast to breakeven

Price target decreased by 20% to US$4.50

Price target decreased by 10.0% to US$5.40

Recent updates

New minor risk - Profitability

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Forecast to breakeven in 2026

Cytosorbents Corporation Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification

Cytosorbents Corporation to Report Q3, 2024 Results on Nov 07, 2024

The Market Lifts Cytosorbents Corporation (NASDAQ:CTSO) Shares 43% But It Can Do More

Cytosorbents Corporation Submits Drugsorb-Atr Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor

Consensus EPS estimates upgraded to US$0.31 loss

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Cytosorbents Corporation Announces Chief Financial Officer Changes

Cytosorbents Corporation to Report Q2, 2024 Results on Aug 13, 2024

CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement

Investors Continue Waiting On Sidelines For Cytosorbents Corporation (NASDAQ:CTSO)

CytoSorbents Corporation Announces Regulatory Approval of CytoSorb® in Taiwan

Cytosorbents Corporation Announces the Launch and Immediate Availability of the PuriFi Blood Pump in the European Union

Cytosorbents Corporation Receives Notice Regarding Nasdaq Minimum Bid Price Requirement

Full year 2023 earnings released: US$0.64 loss per share (vs US$0.75 loss in FY 2022)

No longer forecast to breakeven

Cytosorbents Corporation to Report Q1, 2024 Results on May 09, 2024

Cytosorbents Corporation, Annual General Meeting, Jun 06, 2024

No longer forecast to breakeven

Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

Full year 2023 earnings released

New major risk - Revenue and earnings growth

Cytosorbents Corporation to Report Fiscal Year 2023 Results on Mar 14, 2024

Cytosorbents Corporation Reports Excellent Outcomes from A Groundbreaking Randomized Controlled Trial (Rct) Using Cytosorb® Blood Purification During Heart Transplant, Recently Published in the European Society of Cardiology Journal, Esc Heart Failure

Take Care Before Jumping Onto Cytosorbents Corporation (NASDAQ:CTSO) Even Though It's 28% Cheaper

Price target decreased by 20% to US$4.50

New minor risk - Profitability

Price target decreased by 10.0% to US$5.40

Cytosorbents Corporation Provides Update on the Star-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation

New minor risk - Shareholder dilution

Cytosorbents Corporation has completed a Follow-on Equity Offering in the amount of $10.28501 million.

Cytosorbents Corporation announced that it expects to receive $10.28501 million in funding

New minor risk - Share price stability

Consensus EPS estimates fall by 20%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt?

Cytosorbents Corporation Announces Appointment of Kathleen Bloch as Full-Time CFO

Cytosorbents Corporation Announces Resignation of Alexander D’Amico as Chief Financial Officer, Effective August 28, 2023

CytoSorbents Corporation Completes U.S. and Canadian Star-T Pivotal Trial

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Cytosorbents Corporation to Report Q2, 2023 Results on Aug 01, 2023

CytoSorbents Corporation Appoints Alexander D'Amico as Chief Financial Officer

Shareholders Should Be Pleased With Cytosorbents Corporation's (NASDAQ:CTSO) Price

New minor risk - Share price stability

CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial

Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

Consensus EPS estimates fall by 25%, revenue upgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

CEO & Director exercised options to buy US$97k worth of stock.

Consensus EPS estimates fall by 34%

Full year 2022 earnings released: US$0.75 loss per share (vs US$0.57 loss in FY 2021)

Forecast breakeven date pushed back to 2025

We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

Cytosorbents Corporation to Report Q4, 2022 Results on Mar 09, 2023

CytoSorbents Announces Health Canada Regulatory Approval For Pivotal STAR-T Trial

Cytosorbents Corporation Appoints Irina B. Kulinets as Senior Vice President of Global Regulatory Affairs

Cytosorbents Receives Recommendation from Independent Data and Safety Monitoring Board to Continue Pivotal Star-T Trial as Planned Without Modifications

Consensus EPS estimates fall by 18%

Insufficient new directors

Cytosorbents Announces Pivotal Star-T Trial Reaches First Milestone with 40 Patients Enrolled

Consensus EPS estimates fall by 18%

Consensus EPS estimates fall by 18%

Third quarter 2022 earnings released: US$0.28 loss per share (vs US$0.15 loss in 3Q 2021)

Price target decreased to US$6.67

CytoSorbents Corporation Announces Presentation of Final Key Results from the U.S. Multicenter Cytosorb Therapy

Cytosorbents Corporation to Report Q3, 2022 Results on Nov 03, 2022

CytoSorbents Corporation Announces Retirement of Kathleen P. Bloch, Chief Financial Officer